证券代码：301363 证券简称：美好医疗 公告编号：2025-052 深圳市美好创亿医疗科技股份有限公司 第二届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）第二届董事会 第二十次会议通知于2025年8月8日以书面、电话等方式送达全体董事，并于2025 年8月15日在公司会议室以现场结合通讯方式召开。本次会议由董事长熊小川先 生主持，会议应到董事9人，实际参会董事9人，其中独立董事吴学斌、董事Florian Then、董事Joel Chan以通讯方式参会。经全体与会董事确认，本次会议的召集、 召开以及审议程序符合《中华人民共和国公司法》《公司章程》和《董事会议事 规则》等有关规定，会议形成的决议合法、有效。 二、董事会会议审议情况 经全体与会董事认真审议、充分讨论，会议审议并通过了以下议案： （一）审议通过《关于公司<2025 年半年度报告全文及其摘要>的议案》 公司董事会认为：《2025年半年度报告》及《2025年半年度报告摘要》真实、 准确、完整地 ...

格隆汇8月18日丨美好医疗(301363.SZ)公布2025年半年度报告，上半年营业收入7.33亿元，同比增长 3.73%；归属于上市公司股东的净利润1.14亿元，同比下降32.44%；归属于上市公司股东的扣除非经常 性损益的净利润1.11亿元，同比下降32.08%；基本每股收益0.20元。 ...

美好医疗公告，2025年上半年营业收入7.33亿元，同比增长3.73%。净利润1.14亿元，同比下降 32.44%。公司计划不派发现金红利，不送红股，不以公积金转增股本。 ...

深圳市美好创亿医疗科技股份有限公司 2025 年半年度报告全文 深圳市美好创亿医疗科技股份有限公司 2025 年半年度报告 2025-051 2025 年 8 月 19 日 1 深圳市美好创亿医疗科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人熊小川、主管会计工作负责人严俊峨及会计机构负责人(会计 主管人员)朱娟声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中所涉及的经营计划、发展战略、未来计划等前瞻性陈述不构成 公司对投资者的实质承诺，投资者及相关人士均应当对此保持足够的风险认 识，并且应当理解计划、预测与承诺之间的差异。 公司在本半年度报告中详细阐述了未来可能发生的有关风险因素及对策， 详见"第三节 管理层讨论与分析"之"十、公司面临的风险和应对措施"， 敬请广大投资者注意查阅。 公司需遵守《深圳证券交易所上市公司自律监管指引第 4 号——创业板 行业信 ...

Group 1 - The core viewpoint of the news is that Meihao Medical's stock performance shows a decline, with a current PE ratio of 32.96, significantly lower than the industry average of 56.58 [1][2] - As of August 15, Meihao Medical's market capitalization is 11.787 billion yuan, ranking 66th in the medical device industry based on PE ratio [1][2] - The company has seen a net inflow of 110,700 yuan in principal funds on August 15, with a total inflow of 35.5803 million yuan over the past five days [1] Group 2 - Meihao Medical specializes in the design, development, manufacturing, and sales of precision components and products for medical devices, including home ventilator components and cochlear implant components [1] - The latest quarterly report indicates that for Q1 2025, the company achieved a revenue of 296 million yuan, a year-on-year increase of 5.05%, while net profit was 51.875 million yuan, reflecting a year-on-year decrease of 10.62% [1] - The gross profit margin for the company stands at 39.28% [1]

8月15日，溯联股份大宗交易成交155.66万股，成交额7093.43万元，占当日总成交额的7%，成交价 45.57元，较市场收盘价46.5元折价2%。 ...

来源：金融界 天眼查商业履历信息显示，深圳市美好创亿医疗科技股份有限公司，成立于2010年，位于深圳市，是一 家以从事橡胶和塑料制品业为主的企业。企业注册资本40666万人民币，实缴资本32116万人民币。公司 法定代表人为熊小川。 通过天眼查大数据分析，深圳市美好创亿医疗科技股份有限公司共对外投资了4家企业，参与招投标项 目100次，知识产权方面有商标信息148条，专利信息439条，此外企业还拥有行政许可104个。 金融界消息 截至2025年8月14日收盘，美好医疗（301363）报收于20.94元，上涨3.05%，换手率 14.95%，成交量23.36万手，成交金额4.82亿元。 资金流向方面，今日主力资金净流入2316.72万元，占比成交额4.81%。其中，超大单净流出723.11万 元、占成交额1.5%，大单净流入3039.83万元、占成交额6.31%，中单净流出流入1181.63万元、占成交 额2.45%，小单净流出3498.34万元、占成交额7.26%。 美好医疗最新一期业绩显示，截至2025一季报，公司营业总收入2.96亿元、同比增长5.05%，归属净利 润5187.50万元，同比减少10.62 ...

Core Viewpoint - The medical device sector experienced a decline of 2.16% on August 14, with Lide Man leading the drop, while the Shanghai Composite Index fell by 0.46% and the Shenzhen Component Index decreased by 0.87% [1]. Group 1: Market Performance - The medical device sector's overall performance was negative, with a notable decline in key stocks [1]. - Lide Man's stock price fell by 11.21%, closing at 10.06, with a trading volume of 1.06 million shares [2]. - The sector saw a net outflow of 1.517 billion yuan from major funds, while retail investors contributed a net inflow of 1.269 billion yuan [2]. Group 2: Top Gainers - Botao Biological (688767) saw a significant increase of 19.99%, closing at 45.13 with a trading volume of 104,300 shares and a transaction value of 436 million yuan [1]. - Toukeng Life (300642) rose by 10.85%, closing at 19.10 with a trading volume of 310,100 shares [1]. - Jimin Health (603222) increased by 10.05%, closing at 8.10 with a trading volume of 944,800 shares [1]. Group 3: Notable Decliners - Lide Man (300289) led the decline with a drop of 11.21%, closing at 10.06 with a trading volume of 1.0605 million shares [2]. - Zhonghong Medical (300981) fell by 9.91%, closing at 16.00 with a trading volume of 261,300 shares [2]. - Haitai New Light (688677) decreased by 7.93%, closing at 45.30 with a trading volume of 49,100 shares [2].

Core Points - The Shanghai Composite Index closed at 3666.44 points, slightly down by 0.46%, with a total trading volume of 23062.83 billion yuan [1] - A total of 11 A-shares have surpassed their annual line, with notable stocks showing significant deviation rates, including *ST Xinyuan at 4.65%, *ST Huarong at 4.40%, and Meihua Medical at 2.93% [1] Summary by Category Market Performance - The Shanghai Composite Index is above the annual line, indicating a positive market sentiment despite a minor decline [1] - The total trading volume for A-shares reached 23062.83 billion yuan, reflecting active market participation [1] Stocks Surpassing Annual Line - The stocks with the highest deviation rates include: - *ST Xinyuan: 11.82% increase, 19.23% turnover rate, annual line at 6.06 yuan, latest price at 6.34 yuan, deviation rate of 4.65% [1] - *ST Huarong: 4.94% increase, 0.45% turnover rate, annual line at 7.12 yuan, latest price at 7.43 yuan, deviation rate of 4.40% [1] - Meihua Medical: 3.05% increase, 14.95% turnover rate, annual line at 20.34 yuan, latest price at 20.94 yuan, deviation rate of 2.93% [1] - Other notable stocks with lower deviation rates include: - Hongtaiyang: 2.77% increase, 5.00% turnover rate, annual line at 6.86 yuan, latest price at 7.04 yuan, deviation rate of 2.60% [1] - Xi'an Catering: 3.37% increase, 9.97% turnover rate, annual line at 8.77 yuan, latest price at 8.89 yuan, deviation rate of 1.37% [1] - Supor: 1.27% increase, 0.29% turnover rate, annual line at 51.39 yuan, latest price at 51.90 yuan, deviation rate of 1.00% [1]

Industry Overview - On August 14, the medical device industry experienced a decline of 2.45% with a net outflow of 1.74 billion yuan in principal funds [1] - Among the component stocks, 13 increased while 87 decreased [1] Major Fund Outflows - The companies with the highest net outflows of principal funds included: - Kehua Bio (29.96 million yuan) - Baolait (29.32 million yuan) - Shangrong Medical (28.74 million yuan) - Weisi Medical (26.93 million yuan) - ST Kelly (26.25 million yuan) [1] Notable Stock Performance - Key stocks with significant movements included: - Sainuo Medical: Latest price 30.43, up 3.05%, with a net inflow of 164 million yuan (7.25% of total) [1] - Botao Bio: Latest price 45.13, up 19.99%, with a net inflow of 543.74 thousand yuan (12.47% of total) [1] - Yuyue Medical: Latest price 35.67, down 0.17%, with a net inflow of 49.30 thousand yuan (12.91% of total) [1] - Kefu Medical: Latest price 40.58, up 6.99%, with a net inflow of 470.40 thousand yuan (14.3% of total) [1] - Huatai Medical: Latest price 290.99, down 2.03%, with a net inflow of 297.47 thousand yuan (9.99% of total) [1] - Aohua Endoscopy: Latest price 49.14, down 7.79%, with a net inflow of 2363.53 thousand yuan (10.09% of total) [1] - Meihua Medical: Latest price 20.94, up 3.05%, with a net inflow of 2316.72 thousand yuan (4.81% of total) [1] - Wanfu Bio: Latest price 24.28, down 0.92%, with a net inflow of 184.26 thousand yuan (5.48% of total) [1] - Zhijiang Bio: Latest price 25.24, up 4.87%, with a net inflow of 1420.31 thousand yuan (5.07% of total) [1] - Mairande: Latest price 51.64, up 1.06%, with a net inflow of 1335.64 thousand yuan (2.42% of total) [1]